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cytotoxic T-lymphocyte antigen-4 to potentiate an antitumor T-cell 
response. This agent improved overall survival in a phase III trial in 
previously treated patients with advanced melanoma. Because the 
mechanism of action for ipilimumab is thought to be HLA 
independent, most trials enrolled patients without regard to HLA 
subtype. However, enrollment in the phase III trial was restricted to 
class-I HLA-A*0201-positive patients because two of the three arms 
contained an HLA-A*0201-restricted gp100 vaccine. HLA typing was 
also performed prospectively in several phase II trials and was 
available for 93.5% of patients. In this retrospective analysis, pooled 
efficacy and safety data are presented according to HLA-A*0201 
status and dose from pretreated patients randomized to 0.3, 3, or 
10 mg/kg ipilimumab in four phase II trials. Median overall survival 
(OS) was similar for the 187 HLA-A*0201-positive [9.3 months, 
95% CI (confidence interval) 7.4-11.5] and 266 HLA-A*0201-
negative patients [11.4 months, 95% CI 9.3-15.1] randomized to 
ipilimumab at all doses across the four phase II trials. These data are 
comparable to the OS for the 137 HLA-A*0201-positive patients 
randomized to ipilimumab in the phase III study [10.1 months, 
95% CI 8.0-13.8]. Ipilimumab-induced adverse events and immune-
related adverse events (skin, gastrointestinal, hepatic, other) also 
occurred at similar frequencies among patients in the phase II and III 
trials, regardless of HLA-A*0201 status. These findings support the 
hypothesis that ipilimumab-treated patients with advanced 
melanoma have similar outcomes regardless of their HLA-A*0201 
status.
Keywords: clinical trial, melanoma, ipilimumab, HLA, 
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Introduction
Ipilimumab is a fully human, monoclonal antibody that blocks 
cytotoxic T-lymphocyte antigen-4 to potentiate an antitumor 
T-cell response. The mechanism of action of ipilimumab (i.e., 
cytotoxic T-lymphocyte antigen-4 receptor-ligand interaction) 
is thought to be HLA independent. Ipilimumab improved OS, 
either as monotherapy or combined with a gp100 vaccine, 
compared with a vaccine-only control group, in a phase III, 
randomized, controlled trial in previously treated patients with 
advanced melanoma (MDX010-020) (1). In the MDX010-020 
phase III trial, patients randomized to receive ipilimumab 
monotherapy at 3 mg/kg had a median OS of 10.1 months 
(95% CI 8.0-13.8) compared with 6.4 months (95% CI 5.5-8.7) 
in patients randomized to vaccine alone. The 1- and 2-year OS 
rates with ipilimumab monotherapy were 45.6% and 23.5%, 
respectively, compared with 25.3% and 13.7% with vaccine 
alone. Addition of the gp100 vaccine did not influence the 
survival outcome (hazard ratio 1.04).
Entry criteria for the phase III trial restricted enrollment to 
HLA-A*0201-positive patients because an HLA-A*0201-
restricted gp100 vaccine was used as an active control and in 
combination with ipilimumab. To elicit an immune response, 
peptide vaccines like gp100 must be presented to the immune 
system in the HLA context to which they are restricted. Since the 
gp100 peptide vaccine antigens were originally identified as 
binding to HLA-A*0201, trial enrollment was restricted to 
HLA-A*0201-positive patients. However, this is the only 
ipilimumab trial with a vaccine arm requiring an HLA 
enrollment restriction.
The overall ipilimumab clinical development program is being 
conducted largely without consideration of HLA subtype 
because the mechanism of action of ipilimumab is not related to 
HLA and is therefore likely to be HLA independent. Prospective 
HLA typing was, however, performed in several phase II trials, 
as part of an investigation of potential biomarkers of response or 
safety (1-5). Earlier findings from a pooled analysis of data from 
139 patients with metastatic melanoma in two trials suggested 
that HLA-A*0201 status was not predictive for objective 
response rate to ipilimumab (6). Fifty-four patients received 1 of 6
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Summary of phase II advanced melanoma trials used as data sources for pooled analysis and the comparator phase III study.
Table 2 
HLA-A2*201 status and efficacy (survival, response, and disease control) across phase II trials versus the phase III study.
ipilimumab with peptide vaccination and 85 received intra-
patient, dose-escalated ipilimumab and were randomized to 
receive peptides in accordance with HLA status. The objective 
response rate was 17% in all patients, 18% in HLA-A*0201-
positive patients and 13% in HLA-A*0201-negative patients (6).
This is a retrospective analysis of pooled efficacy and safety 
data stratified by HLA-A*0201 status from 453 pretreated 
patients randomized to 0.3, 3, or 10 mg/kg ipilimumab in four 
phase II trials (CA184-004, -007, -008, and -022). Findings were 
compared with efficacy and safety outcomes from 137 HLA-
A*0201-positive patients on the phase III trial (1).
Results
Patient population
Demographics, disease characteristics, and prior therapies 
were generally similar across all trials. Details of the four phase 
II trials used as data sources for the pooled analysis and of the 
phase III study included for data comparison are shown in 
Table 1 (1-5). The HLA status (HLA-A*0201 positive or 
negative) was evaluated prospectively for the majority of 
patients in MDX010-020 and all four phase II trials (99.7% and 
93.5%, respectively). In the phase II trials, 453 previously treated 
patients were included in the efficacy analyses, of whom 187 
(41.3%) were HLA-A*0201 positive and 266 (58.7%) were HLA-
A*0201 negative. For safety analyses, 450 previously treated 
patients were included, of whom 185 (41.1%) were HLA-A*0201 
positive and 265 (58.9%) were HLA-A*0201 negative. Patients 
were randomized to 0.3, 3, or 10 mg/kg ipilimumab depending 
on the study they participated. Since the 0.3 mg/kg dose appears 
to be below the minimal threshold for an objective response to 
ipilimumab (3) the data were also analyzed in patients 
randomized to either 3 or 10 mg/kg. Patients who initially 
received 0.3 or 3 mg/kg ipilimumab in the phase II CA184-022 
trial were eligible for a roll-over study (CA184-025) in which 
they received ipilimumab at 10 mg/kg.
Efficacy by HLA-A*0201 status
Efficacy data are shown in Table 2. Patients randomized to 
receive ipilimumab at any dose across the phase II trials had 
similar median OS regardless of HLA-A*0201 status (Figure 1). 
When data from patients randomized to a 10 mg/kg ipilimumab 
dose in the four phase II trials were analyzed, median OS was 
slightly higher in the HLA-A*0201-negative than in the HLA-
A*0201-positive group for that dose. However, this trend is 
reversed at the 3 mg/kg dose. The conflicting OS observed in the 
3 and 10 mg/kg subsets suggests there is no correlation with 
HLA status. HLA-A*0201-positive patients randomized to 
ipilimumab 3 mg/kg in two phase II trials (CA184-004/CA184-
022) had a median OS similar to that in patients randomized to 
the same dose in the phase III study (MDX010-020). HLA-
A*0201-negative patients randomized to 3 mg/kg ipilimumab in 
the phase II trials had slightly lower median OS than the HLA-
A*0201 positive patients in the phase III study. These data show 
an expected moderate variability within the populations, and 2 of 6 www.cancerimmunity.org
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Kaplan-Meier plot of overall survival by HLA status. Data from all pretreated patients randomized to 0.3, 3, or 10 mg/kg ipilimumab from four phase II trials pooled 
by dose versus HLA-A2*201-positive patients randomized to 3 mg/kg ipilimumab monotherapy in a phase III trial. Patients in the CA184-022 study who received 0.3 or 
3 mg/kg were eligible for a roll-over study (CA184-025) in which they received ipilimumab at 10 mg/kg.
Table 3 
HLA-A2*201 status and safety (all and drug-related AEs) across phase II trials versus the phase III study.
Table 4 
HLA-A2*201 status and immune-related adverse events (irAEs) across phase II trials versus the phase III study.www.cancerimmunity.org 3 of 6
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Survival rates at 1 and 2 years broadly mirror median OS 
values between groups and doses. Overall, rates were similar in 
HLA-A*0201-positive and -negative patients in phase II and 
phase III trials. However, in the analysis limited to patients 
randomized to 3 mg/kg ipilimumab, survival rates were slightly 
higher in HLA-A*0201-positive patients than in HLA-A*0201-
negative patients; this pattern in survival rates was inverted at 
the 10 mg/kg dose, and in pooled data from patients 
randomized to any ipilimumab dose.
Data for best overall response rate (BORR) and disease control 
rate (DCR) are summarized for the four phase II trials and the 
phase III trial by HLA-A*0201 type and ipilimumab dose in 
Table 2. The BORR and DCR were generally consistent among 
all subgroups regardless of HLA-A*0201 status.
Immune-related adverse events by HLA-A*201 status
Adverse event (AE) and drug-related AE rates were generally 
similar across ipilimumab doses of 3 and 10 mg/kg, and when all 
doses were pooled, regardless of HLA-A*0201 status (Table 3). 
When pooled data from patients in the four phase II trials across 
all ipilimumab doses were compared with data from patients in 
the phase III trial, immune-related adverse events (irAEs) 
occurred at similar frequencies regardless of HLA-A*0201 status 
(Table 4). However, patients receiving 3 mg/kg ipilimumab in 
phase II trials showed a tendency toward a higher frequency of 
irAEs in HLA-A*201-positive patients compared with HLA-
A*0201-negative patients, while this trend was inverted in the 
10 mg/kg dose group (Table 4). This is consistent with the 
observations on survival outcomes in HLA-A*0201-negative or 
-positive patients in the different dosage groups.
Discussion
This analysis shows that HLA-A*0201 status does not have a 
significant correlation with efficacy or toxicity with ipilimumab 
monotherapy. This is consistent with findings from a previous 
analysis of ipilimumab therapy and HLA status in a smaller 
group of phase II patients (6). The efficacy and safety outcomes 
in the phase III trial in HLA-A*0201-positive patients were 
similar to outcomes in the HLA-A*0201-positive and HLA-
A*0201-negative patients in the four phase II trials analyzed. 
These data support that the mechanism of action of ipilimumab 
is independent of HLA status.
In this analysis, 41.3% of the 453 patients from the phase II 
trials who were evaluable for efficacy were HLA-A*0201 
positive. This is consistent with the proportion of HLA-A*0201-
positive individuals in the general population (7-9). OS was 
similar in HLA-A*0201-positive and HLA-A*0201-negative 
patients. However, there was an apparent increase in OS in 
patients who were HLA-A*0201-negative compared with HLA-
A*0201-positive patients randomized to the 10 mg/kg dose of 
ipilimumab and in the pooled data; however this finding was not 
statistically significant. This was accompanied by a 
corresponding trend toward an increased frequency of both 
overall and grade 3 or higher irAEs in HLA-A*0201-negative 
patients, consistent with previous observations of an association 
between ipilimumab efficacy and mechanism-related irAEs (5, 
6, 10-14). In contrast, in patients randomized to 3 mg/kg 
ipilimumab, OS and frequency of irAEs tended to be higher in 
HLA-A*0201-positive than -negative patients (also not 
statistically significant).
This pooled analysis of data from four phase II trials suggests 
that there is no apparent correlation between HLA-A2*0201 
status and efficacy and safety outcomes in ipilimumab treated 
patients. However, there may be small trends that are 
inconsistent in direction by dose level that represent statistical 
variability rather than a biologic effect. This is particularly 
relevant to the small survival advantage observed for HLA-
A2*0201-negative patients in the 10 mg/kg group and the 
similarly small disadvantage in the 3 mg/kg group. Confidence 
intervals for these data were overlapping and the observations 
seem to be driven by the sample size of the cohorts as the 
differences reduce as the sample sizes increase. Overall, the 
retrospective use of data pooled from several studies is a 
limitation, and imbalances among the populations may account 
for differences in efficacy and safety. Regardless of the small 
differences among HLA-A2*0201-positive and -negative 
patients at the different doses, the 1-year OS rates ranged from 
39.0% to 54.1% and these values are similar to those for the 
ipilimumab-containing arms in the phase III trial (43.6% and 
45.6%) (1). These OS rates also compare favorably with that of 
the vaccine-only control arm in the phase III trial (25.3%) (1) 
and the overall mean 1-year survival rate of 25% reported from a 
meta-analysis of 68 phase II trial arms (15).
BORR and DCR were comparable between the MDX010-020 
phase III trial and pooled response data from the four phase II 
trials. Other immunotherapies (with HLA-independent 
mechanisms of action) also provide benefit regardless of HLA 
status. An extensive analysis of prospectively collected data from 
272 patients with metastatic melanoma receiving interleukin-2-
based treatment showed no significant correlation between 
HLA-A*02 expression and response (16). In another study, there 
was no association between response and HLA-A*02 expression 
in 54 patients with metastatic melanoma, including 16 
responders and 16 patients with stable disease, who were treated 
with interferon-alfa and interleukin-2 (17).
Clinical data linking HLA subtype to any melanoma-related 
risk are limited; observations in the small number of evaluations 
have not been replicated and none of the putative associations 
involve the A*0201 allele (18-20). Moreover, HLA 
characterization does not play any role in the clinical staging and 
classification of melanoma based on validated prognostic factors 
(validation based on approximately 50,000 patients) (21). HLA-
A*02 was not a gene predictive of outcome in 284 high-risk 
melanoma patients receiving adjuvant interferon (22).
In summary, this retrospective analysis shows that the survival 
and toxicity outcomes are generally similar in HLA-A*0201-
positive and HLA-A*0201-negative patients who received 
ipilimumab in the phase II trials, and in the HLA-A*0201-
positive patients who received ipilimumab alone in the phase III 
trial. These data support the hypothesis that HLA-A*0201 status 
is not a predictive factor for ipilimumab efficacy or safety.
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Materials and methods
Data sources
Details of study design, dosing regimens, and patient 
demographics for the phase II and phase III trials have been 
reported elsewhere (1-5). Only data from pretreated patients for 
whom HLA type was available were included for analysis. 
Analytical methods
In trials CA184-004, -022, -008, and -007, the limited 
specificity of the initial HLA-A*02 supergroup identification, 
which used the Innogenetics INNO-LiPA HLA assay (this assay 
uses a DNA line-probe methodology and is not FDA approved), 
meant that a second step to achieve full genomic sequencing of 
the allelic site (specific allelic identification using the FDA-
approved Genovision/Qiagen Olerup SSP TM-Assay) was 
required in every case.
In the MDX010-020 phase III study, the required study-based 
HLA testing was performed using the Invitrogen™ SSP UniTray® 
polymerase chain reaction (PCR)-based assay, which is FDA 
approved for in vitro diagnostic use, using HLA primers 
provided by Invitrogen™. Samples from this study that gave 
ambiguous results using the Invitrogen™ assay kit were referred 
for full genomic sequencing of the allelic site; this sequenced-
based typing was carried out using the HLA-AlleleSEQR kit 
from Applied BioSystems. In the MDX010-020 dataset, only 9 
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